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Abstract – Porcine reproductive and respiratory syndrome virus (PRRSV) causes severe economic losses
in the pig industry worldwide. Currently, vaccines based on inactivated PRRSV provide limited protection
of pigs against infection, most likely because viral epitopes associated with the induction of neutralizing
antibodies are not or poorly conserved during inactivation. To analyze the effect of inactivation procedures
on the interaction of PRRSV with receptors involved in virus entry, a new assay was set up in this study.
Viral entry-associated domains are most likely important for the induction of neutralizing antibodies, since
neutralizing antibodies block interaction of PRRSV with cellular receptors. To investigate the interaction of
PRRSV with the cellular receptors upon different inactivation procedures, attachment to and internalization
of inactivated PRRSV into macrophages were monitored. AT-2 could not inactivate PRRSV completely and
is therefore not useful for vaccine development. PRRSV inactivated with ultraviolet light, binary
ethyleneimine and gamma irradiation, which all mainly have an effect at the genomic level, showed no
difference compared to control live virus at all levels of virus entry, whereas PRRSV treated with
formaldehyde, glutaraldehyde and pH changes, which all have a modifying effect on proteins, was not able
to internalize into macrophages anymore. These results suggest that inactivation with methods with a main
effect on the viral genome preserve PRRSVentry-associated domains and are useful for future development
of an effective inactivated vaccine against PRRSV. Although PRRSV incubation at 37 C can completely
inactivate PRRSV with preservation of entry-associated domains, this method is not recommended for
vaccine development, since the mechanism is yet unknown.
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1. INTRODUCTION
Porcine reproductive and respiratory syn-
drome virus (PRRSV) is a single-stranded
enveloped RNA virus which is assigned to
the family Arteriviridae [11, 26, 37], together
with lactate dehydrogenase-elevating virus
(LDV), equine arteritis virus (EAV), and
simian hemorrhagic fever virus (SHFV). The
Arteriviridae as well as the Coronaviridae
and Roniviridae belong to the order Nidovi-
rales [6, 12, 26].
PRRS is worldwide recognized as the eco-
nomic most important viral pig disease [44].
Infection of pregnant sows may result in mum-
miﬁed and weak-born piglets, elevated pre-
weaning mortality and abortion [9, 35, 59].* Corresponding author: hans.nauwynck@ugent.be
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Infected boars may show a temporary decrease
of sperm quality and virus shedding via sperm
[51]. This virus shedding may lead to virus
transmission to sows. Besides its effect on
reproduction, PRRSV is also involved in the
multifactorial respiratory disease complex in
pigs, where the virus facilitates secondary bac-
terial infections and respiratory problems in
pigs of all ages [55, 59].
Two main types of vaccines are currently
used to prevent PRRSV infection, modiﬁed live
virus (MLV) vaccines and killed virus (KV)
vaccines [34, 68]. Commercial MLV and KV
vaccines exist, but both have some disadvan-
tages. MLV vaccines induce an immune
response that can protect pigs against PRRSV
infection, however only when the virus is not
too distant from the vaccine strain [28, 29].
Attenuated viruses may cause safety problems.
Some MLV vaccines may spread transplacen-
tally [18, 36, 46], be shed via semen and reduce
semen quality [10, 47], and may even revert to
virulence [45]. KV vaccines are safe to use, but
currently used KV vaccines insufﬁciently pro-
tect pigs against viremia upon challenge, since
both magnitude and duration of viremia were
not different between vaccinated and control
animals [68]. A comparative study of MLV
and KV vaccines in boars showed that while
vaccination with an MLV vaccine decreased
viremia and virus shedding in semen, vaccina-
tion with a KV vaccine did not change onset,
duration or level of viremia, or virus shedding
in semen [47]. Preliminary experiments in our
lab showed that while an experimental inacti-
vated PRRSV vaccine was able to induce neu-
tralizing antibodies, it could only partly block
viremia after challenge [41]. The current incom-
plete protection of KV vaccines against PRRSV
infection might be caused by an over-inactiva-
tion of the virus, resulting in destruction of neu-
tralizing viral epitopes. Neutralizing viral
epitopes induce the production of neutralizing
antibodies by the host, which are necessary
for neutralization of the virus and reduction of
overall infection. As a result, destruction of
the neutralizing epitopes by over-inactivation
will reduce the number of neutralizing antibod-
ies raised by the host, which will ultimately lead
to less efﬁcient protection against a viral
challenge.
To our knowledge, currently used KV vac-
cines against PRRSV have been evaluated for
the quantity of viral antigens, but not the qual-
ity. For other viruses, the quality has been
examined. For example, the effect of inactiva-
tion of inﬂuenza virus is investigated by mea-
suring the hemagglutinating activity before
and after inactivation [19]. For HIV, the attach-
ment of neutralizing antibodies to viral epitopes
is determined after inactivation by an enzyme-
linked immuno sorbent assay (ELISA) [25,
50]. ELISA as a tool for quality control of the
antigen is also used for rabies virus [21, 53]
and poliovirus vaccines [43]. Quality control
for PRRSV cannot be performed using the
same methods as for HIV and inﬂuenza,
because of the limited knowledge of PRRSV
neutralizing epitopes. There are some neutraliz-
ing epitopes known on GP5 and GP4 [39, 48,
66] and there are possibly also neutralizing epi-
topes on GP3 [5], but it is not known if other
important epitopes exist and which neutralizing
epitopes are most important. Previous results
from our lab showed that PRRSV neutralizing
antibodies block infection by preventing the
interaction of PRRSV with the internalization
receptor sialoadhesin (Sn) on the target cells,
macrophages [15, 16, 60, 61]. This indicates
that neutralizing antibodies are directed to the
viral epitopes that are involved in the attach-
ment to the PRRSV receptors and internaliza-
tion into the macrophage [15]. Based on this
observation, a quality control of the viral anti-
gen of a PRRSV KV vaccine was developed,
by monitoring PRRSV attachment to and inter-
nalization into macrophages before and after
inactivation. An ideal killed PRRSV vaccine
should be able to attach to and internalize into
macrophages during a quality-control assay,
but it should be disabled to replicate in order
to avoid viremia.
The aim of this study is to investigate
the effect of different PRRSV inactivation
methods on the viral entry-associated domains.
To this end, inactivated PRRSV attachment to
and internalization into macrophages were
monitored.
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2. MATERIALS AND METHODS
2.1. Cells and virus
The European PRRSV strain, Lelystad virus (LV)
[63], grown on Marc-145 cells (4th passage) was
used for inactivation. Marc-145 cells cultivated
in minimum Eagle’s medium (MEM) with 5%
fetal bovine serum (FBS), 0.3 mg/mL glutamine,
100 U/mL penicillin, 0.1 mg/mL streptomycin and
0.1 mg/mL kanamycin were used for LV production
and titration. Virus attachment and internalization
were investigated in macrophages cultivated in
RPMI 1640 with 10% FBS, 100 U/mL penicillin,
0.1 mg/mL streptomycin, 0.1 mg/mL kanamycin,
0.1 mg/mL gentamycin, 0.01 mg/mL tylosin,
0.3 mg/mL glutamine, 1 mM nonessential amino
acids and 1% sodium pyruvate (100·) for 24 h.
2.2. PRRSV concentration and puriﬁcation
The European PRRSV strain, LV, was grown on
Marc-145 cells. The medium containing the virus
was puriﬁed as described by Delputte et al. [15], this
with some modiﬁcations to allow puriﬁcation of
larger quantities of virus. Virus supernatant was ﬁrst
ﬁltrated through a 0.45 lm ﬁlter and then ultra-
centrifuged for 2 h at 31 000 rpm with a rotor type 35
at 4 C (Beckmann Coulter, Analis, Ghent, Belgium)
to pellet the virus. The resuspended virus pellet was
centrifuged 10 min at 13 000 rpm (Heraeus fresco,
Thermo Fisher Scientiﬁc, Zellik, Belgium) to remove
cell debris and large aggregates and the supernatant
was ultra-centrifuged through a 30% sucrose cushion
for 3 h at 30 000 rpm with a SW 41 Ti rotor at 4 C
(Beckmann Coulter). Finally, the virus pellet was
resuspended in 1 mL PBS by incubating it for 1 h
on ice.
2.3. Inactivation methods
An overview of the inactivation methods used
and their mode of action is shown in Table I. Puriﬁed
virus (107 TCID50/mL) was used for inactivation.
For inactivation with formaldehyde, glutaraldehyde
or 2,2-dithiodipyridine (AT-2), virus was incubated
for 4 h at 37 C with different concentrations formal-
dehyde (Sigma, Bornem, Belgium) [14, 54], glutaral-
dehyde (Sigma) [14] or AT-2 (Aldrich, Bornem,
Belgium) [7, 54]. Formaldehyde, glutaraldehyde
or AT-2 was afterwards removed by ultracentrifuga-
tion. For inactivation by changing the pH, the pH
was adjusted with HCl and NaOH and virus was
incubated for different times at a pH2 or at a pH12.
After incubation, the pH was neutralized [14]. For
temperature inactivation, virus was incubated for dif-
ferent times at 37 C [14, 33]. Inactivation of PRRSV
with gamma irradiation was performed using an elec-
tron accelerator (Prof. L. Van Hoorebeke, Ghent
University, Faculty of Science, Department of
Subatomic and Radiation Physics). For PRRSV inac-
tivation with ultraviolet (UV) radiation, virus was
radiated with UV light from a UV cross-linker
(BRS, Drogenbos, Belgium) [14]. Inactivation with
binary ethyleneimine (BEI) was performed by incu-
bating virus with 1 mM BEI (Aldrich) for different
times at 37 C. The reaction was stopped with
0.1 mM sodium thiosulfate (Sigma) [2, 42].
2.4. Analysis of virus inactivation
Virus titration was performed on 3 days cultivated
Marc-145 cells following the standard procedure [3].
After 5 days, occurrence of cytopathic effect (CPE)
was investigated and the 50% tissue culture infective
dose (TCID50) was calculated.
To conﬁrm that all virus was completely inacti-
vated using selected inactivation procedures, either
a complete dose (107 TCID50/mL virus) or 10· more
virus was inactivated and used for inoculation of
Marc-145 cells, followed by two blind passages.
The Marc-145 cells were investigated every week
for CPE and cells were stained by immunoperoxidase
monolayer assay (IPMA) [30]. Additionally, a bioas-
say was also done for selected inactivation methods
by injecting 107 TCID50/mL inactivated PRRSV in
RPMI 1640 medium intramuscularly in a pig. Blood
was taken every week and serum was checked for
viremia by virus titration and PRRSV speciﬁc anti-
bodies by IPMA up to 2 weeks post inoculation.
2.5. Effect of PRRSV inactivation on virus
attachment, internalization, disassembly
and infection by immunoﬂuorescence
staining
For the detection of PRRSV during the course of
PRRSV infection, macrophages were inoculated with
untreated or treated PRRSV (moi 2) for 1 h at 4 C
or 1, 5 and 10 h at 37 C, ﬁxed with methanol at
20 C and stained as described by Delputte et al.
[15]. Brieﬂy, the capsid protein was stained with a
primary antibody P3/27 [64] and a secondary anti-
body ﬂuorescein isothiocyanate (FITC)-conjugated
goat polyclonal anti-mouse immunoglobulins
(Molecular Probes, Invitrogen, Merelbeke, Belgium).
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Avirus stock with a ratio of 1/100 of infectious virus/
non-infectious virus was used for inoculation. This is
determined by application of diluted samples of virus
suspension to glass slides, ﬁxed with methanol and
stained against nucleocapsid as described above. This
showed that the virus stock with 106 TCID50/mL
contained approximately 108 particles/mL. Confocal
analysis was performed using a TCS SP2 laser scan-
ning spectrum confocal system (Leica Microsystems
GmbH, Heidelberg, Germany) to determine the
amount of internalized PRRSV. The numbers of
bound and internalized PRRSV were counted from
the acquired images. The amount of internalized
PRRSV of both treated and untreated virus in a
macrophage were determined by counting the small
ﬂuorescently labeled dots and set relatively to inter-
nalized untreated virus.
2.6. Inhibition of phagocytosis
Macrophages were pre-treated for 30 min with
0.1 lM wortmannin to block phagocytosis. After-
wards the macrophages were inoculated with
untreated or treated virus for 1 h at 37 C in the pres-
ence of 0.1 lM wortmannin. Then the cells were
ﬁxed with methanol at 20 C and stained as
described by Delputte et al. [15]. Brieﬂy, the capsid
protein was stained with a primary antibody P3/27
[64] and a secondary antibody FITC-conjugated goat
Table I. Overview of the inactivation methods used to inactivate PRRSV.
Method Type Mechanism
Formaldehyde Alkylating agent Monohydroxy-methylizing of adenine [1]
Cross-linker Cross-linking of RNA to capsid proteins [20, 27, 32],
causing a block of genome reading [49]
Cross-linking of proteins by formation of inter- and intramolecular
methylene bridges between hydroxymethylated amines [22]
Glutaraldehyde Cross-linker Cross-linking of proteins by the same mechanism as
formaldehyde described above [8]
AT-2 Cross-linker Cross-linking of proteins by oxidation of S-H groups causing
formation of S-S bridges which results in a covalent modiﬁcation
and functional inactivation of S-H-containing
internal viral proteins [7]
pH Denaturation agent Denaturation of proteins, the conformation of spike proteins of
coronaviruses for example enables fusion of the virus with the
host cell by changes to a pH of 8 [62]
Temperature Denaturation agent A high temperature denaturates proteins. As a result, the
conformation of viral proteins that are involved in attachment
and replication in a host cell may have changed [31, 56]
Gamma irradiation Radiation Viruses are inactivated primarily by direct damage,
via disruption of the genome [24]
Formation of free radicals which damage proteins [24]
UV light Radiation Induction of dimer formation between adjacent uracils in
RNA [40, 57]. Dimer formation leads to pressure and
breakage of the sugar backbone causing a block of
genome reading
More slowly, UV also causes structural modiﬁcations of the
capsid proteins resulting in the formation of large and small
photoproducts [40, 58]
BEI Alkylating agent Alkylation of RNA at low concentrations. Most likely genome
reading is blocked by alkylation of guanine or adenine by BEI [4, 23]
Alkylation of proteins (nucleocapsid) at high concentrations [4]
Vet. Res. (2009) 40:62 I. Delrue et al.
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polyclonal anti-mouse immunoglobulins (Molecular
Probes, Invitrogen). Confocal analysis was performed
to check for endocytosis.
2.7. Analysis of the viral proteins of inactivated
PRRSV by SDS-PAGE and Western
blotting
SDS-PAGE, Western Blotting and ECL of viral
proteins were performed essentially as described by
Delputte et al. [17]. The membranes were stained
for 1 h with a primary mouse monoclonal antibody
against one of the proteins of LV, M (126.3) [38],
N (P3/27) [64], GP5 (4BE12) [52], GP4 (122.29)
[39], GP3 (P9A3-20) (Intervet, Boxmeer, the
Netherlands) or pig polyclonal antibody.
3. Results
3.1. Effect of different treatments on PRRSV
infectivity
To test the potential of the different PRRSV
inactivation treatments, puriﬁed virus (107
TCID50/mL) was treated with formaldehyde,
glutaraldehyde, AT-2, pH, 37 C, gamma irra-
diation, UV light or BEI, using different con-
centrations, time periods and/or doses. Treated
PRRSV was titrated to determine an inactiva-
tion curve (Fig. 1). There was no infectious
virus detected when PRRSV was treated with
the lowest concentration of formaldehyde
(0.1 lg/mL) (Fig. 1A), the lowest gamma irra-
diation dose (0.25 kGy) (Fig. 1F), the lowest
UV irradiation dose (100 mJ/cm2) (Fig. 1G),
or at the ﬁrst time point investigated for inac-
tivation with pH2 (1 h) (Fig. 1D), pH12 (data
not shown), and BEI (6 h) (Fig. 1H). For
glutaraldehyde, the amount of infectious virus
decreased in function of the concentration
and no infectious virus could be detected upon
incubation with a concentration of 0.5 lg/mL
glutaraldehyde or more (Fig. 1B). PRRSV
was still infectious after 4 h incubation
at 37 C with the highest concentration of
2 mM AT-2 (Fig. 1C). For 37 C treatment,
the amount of infectious virus decreased in a
time dependent way and there was no infec-
tious virus detected after 48 h incubation at
37 C (Fig. 1E). For formaldehyde, glutaralde-
hyde and AT-2, the titer at time point 0 was
lower than 107 TCID50/mL, because of loss
of some virus during ultracentrifugation. These
results showed that for all inactivation meth-
ods, except for AT-2, a minimal treatment that
allowed complete virus inactivation could be
determined.
3.2. Effect of different inactivation procedures
on virus internalization into macrophages
To investigate the preservation of the entry-
associated domains of the treated PRRSV, an
immunoﬂuorescence staining was performed
to determine whether internalization of inacti-
vated PRRSV into macrophages was still
possible. The results of these internalization
experiments are shown in Figures 2 and 3.
PRRSV inactivated with 1 lg/mL formalde-
hyde (Figs. 2A and 3), 50 lg/mL glutaralde-
hyde (Figs. 2B and 3), pH2 (Figs. 2D and 3)
or pH12 (data not shown) for 1 h was
no longer able to internalize into macro-
phages. The internalization experiments with
AT-2 inactivated PRRSV (Figs. 2C and 3)
showed that PRRSV treated with all concen-
trations of AT-2 tested, could still internalize
into macrophages, but this was to be expected
since the virus was still infectious even at
the highest concentration of AT-2. The inter-
nalization experiments for 37 C and BEI
inactivation (Figs. 2E, 2H and 3) showed that
PRRSV incubated at 37 C or treated
with 1 mM BEI could still internalize into
macrophages for all time points investigated.
PRRSV treated with all doses of gamma
irradiation or UV examined could still inter-
nalize into macrophages, but the internaliza-
tion diminished in a dose dependent way
for gamma irradiation inactivated PRRSV
(Figs. 2F, 2G and 3).
Together, these data show that the entry-
associated domains were not preserved when
PRRSV is inactivated with formaldehyde, glu-
taraldehyde or pH changes, while they were
preserved using AT-2, 37 C, gamma irradia-
tion, UV or BEI. About 20% of the cells inoc-
ulated with PRRSV inactivated with methods
Optimization of PRRSV inactivation Vet. Res. (2009) 40:62
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that still allowed internalization, showed inter-
nalization, because untreated PRRSV infects
only about 20% of the macrophages in vitro.
From the cells inoculated with PRRSV inacti-
vated with methods that did not allow internal-
ization anymore, there were no cells that
showed internalization at all.
3.3. Effect of the different inactivation methods
on different stages in the virus replication
cycle in macrophages
PRRSV inactivated with formaldehyde,
glutaraldehyde and pH changes was not able
to internalize into macrophages, which is a
Figure 1. Effect of different inactivation methods on PRRSV infectivity. Untreated LV or inactivated LV
was titrated on 3 days cultured Marc-145 cells to determine presence of infectious virus in the samples. The
dotted line resembles the detection limit of the assay.
Vet. Res. (2009) 40:62 I. Delrue et al.
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crucial step in the viral replication cycle.
Because internalization did not occur, the
uncoating, virus replication, assembly and
release did also not occur (Fig. 3).
PRRSV inactivated by 37 C, gamma irra-
diation, UV and BEI could still internalize
into macrophages, thus it was able to perform
this step of the viral replication cycle. After
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Figure 2. Effect of different inactivation methods on PRRSV internalization. Macrophages were incubated
with untreated LVor inactivated LV for 1 h. After 1 hpi, the virus was stained by immunoﬂuorescence and
internalization of PRRSV particles was determined by confocal microscopy. The amount of internalized
PRRSV particles of both treated and untreated virus in a macrophage were counted by counting the small
ﬂuorescently labeled dots and set relatively to internalized untreated virus.
Optimization of PRRSV inactivation Vet. Res. (2009) 40:62
(page number not for citation purpose) Page 7 of 15
5 h, the uncoating occurred, thus also the sec-
ond step of the viral replication cycle could
be performed. The inactivated virus was how-
ever not capable of replicating and this thus
conﬁrmed the completely inactivated status
of the virus (Fig. 3).
3.4. Inhibition of phagocytosis to conﬁrm
receptor-mediated endocytosis after
inactivation
To investigate if entry of the inactivated
PRRSV in macrophages occurred via Sn and
CD163 as described for infectious PRRSV
[60, 61], and not simply taken up by phagocy-
tosis, entry was also determined using a
phagocytosis inhibitor wortmannin. After treat-
ment of the macrophages with the phagocyto-
sis inhibitor wortmannin, untreated PRRSV
still attached to and internalized into macro-
phages. PRRSV inactivated with UV and
BEI also attached to and internalized into mac-
rophages, whereas formaldehyde and glutaral-
dehyde inactivated PRRSV could not attach
and internalize.
3.5. Safety test to conﬁrm complete inactivation
Gamma irradiation, UV and BEI seemed to
be useful methods for killed PRRSV vaccine
development, since the inactivated virus
attaches and enters macrophages in a similar
way as the virulent virus. Therefore, safety
tests were done to conﬁrm that the inactivated
virus was completely inactivated and safe for
use in pigs. First, 107 TCID50/mL virus was
inactivated and Marc-145 cells were inoculated
for two passages with the inactivated virus.
This test indicated that virus inactivated with
0.25 kGy gamma irradiation, 100 mJ/cm2
UV or 6 h incubation with BEI were com-
pletely inactivated (data not shown). To be
sure the virus was inactivated, 1.5 kGy gamma
irradiation, 1 000 mJ/cm2 UV or 24 h incuba-
tion with BEI were selected as a safe method
to inactivate PRRSV. A second test was per-
formed by inactivating a higher concentrated
virus suspension under the same conditions
(108 TCID50/mL virus). The results demon-
strated that 1 000 mJ/cm2 UV or 24 h incuba-
tion with BEI could still completely inactivate
10 times more virus (data not shown). Virus
(108 TCID50/mL virus) inactivated with
gamma irradiation was not completely inacti-
vated with a dose of 1.5 kGy and starting
from a dose of 2 kGy, the preservation of
Figure 3. Effect of different inactivation methods
on different stages of the viral replication cycle.
Macrophages were incubated with inactivated LVor
untreated LV for 1 h at 4 C and 1, 5 or 10 h at
37 C. After ﬁxing and immunoﬂuorescence stain-
ing of the cells, attachment (1 hpi at 4 C),
internalization (1 hpi at 37 C), disassembly (5 hpi
at 37 C) and replication (10 hpi at 37 C) was
analyzed by confocal microscopy.
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entry-associated domains decreases. Therefore,
inactivation with gamma irradiation is not use-
ful for further vaccine development. Finally, to
conﬁrm complete inactivation, a bioassay was
performed. Therefore, 107 TCID50/mL virus
was inactivated with 1 000 mJ/cm2 UV or
24 h incubation with BEI and intramuscularly
injected in pigs. Viremia was not detected up
to 2 weeks after injection, while virus speciﬁc
antibodies were induced, which suggests that
the virus was completely inactivated and safe
to use in pigs (data not shown).
3.6. Western blot analysis of the viral proteins
of inactivated PRRSV
The effect of different inactivation methods
on viral proteins was further investigated by
analyzing the protein pattern of the virus
before and after inactivation by Western blot-
ting (Fig. 4, Tab. II). Under reducing as well
as under non-reducing circumstances, all the
viral proteins were present after inactivation
with formaldehyde, AT-2 and gamma irradia-
tion, but to a lesser extent as untreated
PRRSV. For glutaraldehyde, under reducing
as well as under non-reducing conditions not
all the viral proteins could be detected after
inactivation. The protein pattern of the virus
before and after inactivation by UV irradiation
was not identical, which suggests that UV irra-
diation resulted in the degradation of the viral
proteins. For pH changes, 37 C and BEI all
the viral proteins were present after inactiva-
tion. Complexes like N-dimer and M-GP5
however were more degraded in comparison
to the untreated virus when treated with pH
changes.
The formaldehyde, glutaraldehyde, pH,
AT-2, gamma irradiation and UV inactivated
PRRSV did not have the same protein pattern
as the untreated virus. These results indicated
that with these inactivation procedures inacti-
vated PRRSV did not resemble infectious
PRRSV. The 37 C and BEI inactivated
PRRSV showed the same protein pattern as
the untreated virus. These results suggest that
PRRSV inactivated at 37 C or by BEI resem-
bles infectious PRRSV.
4. DISCUSSION
Virus inactivation procedures with the aim to
develop inactivated virus vaccines should have
two major goals: complete inactivation of infec-
tious virus (safety), while conserving epitopes
of the inactivated virus that are important for
the induction of protective immunity (antigen
quality). This study aimed to test different inac-
tivation procedures for PRRSV to evaluate the
effect on both reduction of infectivity and con-
servation of viral entry-associated domains, the
latter being a measure for the quality of the anti-
gen used.
Currently, there are no data available in liter-
ature on inactivation procedures of PRRSV.
Therefore, inactivation methods and conditions
used in this study are based on studies where
inactivation of other viruses was evaluated.
Evaluation of the capacity of different inactiva-
tion procedures to completely inactivate
PRRSV showed similarities and differences
with that of other viruses. PRRSV could not
be inactivated with AT-2, not even after treat-
ment with 2 mM for 4 h at 37 C, while HIV
type 1 is already inactivated with 100 lM
AT-2 after 1 h at 37 C [54]. AT-2 modiﬁes free
thiol groups of internal viral proteins like the
nucleocapsid of HIV-1, more speciﬁcally zinc-
ﬁnger motifs important for HIV-1 infection,
leaving disulﬁde bridges of glycoproteins in
the virus envelope unaffected [7, 65], but for
PRRSV the formation of homodimers of nucle-
ocapsid proteins via disulﬁde bridges is impor-
tant for virus infection [67]. Since PRRSV
seems not to be sensitive for AT-2, this product
cannot be used to develop an inactivated
PRRSV vaccine. For PRRSV inactivation with
formaldehyde and glutaraldehyde, respectively
0.1 and 0.5 lg/mL for 4 h at 37 C was sufﬁ-
cient. In comparison, HIV-1 can be inactivated
with 2 lg/mL formaldehyde after 24 h at
37 C [54] and SARS-CoV with 90 lg/mL
formaldehyde or 20 lg/mL glutaraldehyde after
24 h at 37 C [14]. For PRRSV inactivation by
changing the pH, incubation of the virus at a
pH2 or pH12 for 1 h at 37 C was effective.
Also SARS-CoV could be inactivated after
incubation of 1 h at 37 C at a pH2 or pH12
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[14]. Incubation of PRRSV for 48 h at 37 C
was efﬁcient for its inactivation, while SARS-
CoV was inactivated after incubation of 20 min
at 56 C [14] and adenovirus type 5 after
10 min at 50 C [33]. For this study, inactiva-
tion of PRRSV at higher temperatures was not
considered, since PRRSV proteins, similar to
what is observed with other viruses [56], will
most likely be denaturated, thereby destroying
important epitopes. PRRSV inactivation with
gamma irradiation or UV could be achieved
with an irradiation dose of respectively
0.25 kGy or 100 mJ/cm2. SARS-CoV could
not be inactivated with gamma irradiation, even
not after an irradiation dose of 15 000 rad. For
inactivation with UV, an irradiation dose of
3614 mJ/cm2 was needed [14]. BEI inactiva-
tion of PRRSV could be achieved with 1 mM
BEI after 6 h incubation at 37 C. Berhane
et al. [2] inactivated Nipah virus with 3 mM
BEI for 24 h at room temperature and Mondal
et al. [42] used 1.6 mM BEI for 24 h at 37 C
to inactivate rabies virus. In conclusion, for all
tested inactivation procedures, except for
AT-2, conditions that allowed PRRSV inactiva-
tion could be determined.
Besides inactivation, conservation of viral
entry-associated domains is equally important
Table II. Density of Western blots.
Control UV BEI 37 C Gamma irradiation Formaldehyde Glutaraldehyde AT-2 pH2
N 100 48 103 85 83 30 6 26 82
M 100 14 65 46 48 23 6 23 40
GP5 100 56 95 87 56 42 1 50 75
GP4 100 73 93 91 50 50 13 28 83
GP3 100 47 94 95 39 83 5 83 94
N dimer 100 45 83 92 66 43 0 43 31
M-GP5 100 58 87 92 80 73 0 63 67
Figure 4. Effect of different inactivation methods on PRRSV proteins. Western blot analysis of untreated
LV or inactivated LV in reducing (A) and non-reducing (B) conditions.
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for the development of an inactivated virus vac-
cine. An in vitro assay to check the conserva-
tion of viral domains that are important for
the induction of a protective immunity is pre-
ferred to avoid time consuming vaccination
studies and to allow precise ﬁne tuning of inac-
tivation methods. For inﬂuenza virus and HIV
for example, the major neutralizing epitopes
are known and an in vitro assay to analyze
the conservation of these domains after inacti-
vation can be performed by measuring haemag-
glutination for inﬂuenza virus [19] or by ELISA
for HIV [25]. However, for PRRSV there is
currently no in vitro assay to evaluate this due
to a limited knowledge on the PRRSV neutral-
izing epitopes. In our lab, it was shown that
neutralizing antibodies were preventing infec-
tion by disturbing entry of the virus into macro-
phages [15]. Therefore, it was hypothesized that
viral domains important for viral entry (entry-
associated domains) are also important for the
induction of viral neutralizing antibodies. In this
study, different inactivation methods for
PRRSV were analyzed for their effect on the
viral domains important for entry into macro-
phages, which are most likely also important
for the induction of neutralizing antibodies.
Our experiments with formaldehyde, glutaral-
dehyde and pH inactivated PRRSV suggest that
the viral entry-associated domains are modiﬁed,
since the virus can no longer attach to and inter-
nalize into macrophages. Similarly, Western
blotting showed that the viral proteins were
not or to a lesser extent present, which is prob-
ably due to cross-linking of proteins by formal-
dehyde and glutaraldehyde or denaturation of
viral proteins by pH changes. Formaldehyde
and glutaraldehyde are known to have a similar
effect on proteins, as they are able to induce
protein cross-linking [1, 8, 22], while pH
changes affect proteins by denaturation [62].
Cross-linking or denaturation of viral domains
that are involved in attachment and internaliza-
tion of PRRSV might interfere with the subse-
quent presentation of viral domains to cells
of the adaptive immune system. As a result,
inactivation with formaldehyde, glutaraldehyde
and pH changes will probably give a poor
preservation of viral immunogenicity [13, 54].
In conclusion, formaldehyde, glutaraldehyde
and pH changes are not effective methods to
inactivate PRRSV with preservation of the
entry-associated domains and for future vaccine
development.
Because gamma irradiation mainly has an
effect at the genomic level, one could assume
that this would be an effective method to inac-
tivate PRRSV. However, the range between
complete inactivation and preservation of the
entry-associated domains was too small to use
this method in a safe way for vaccine develop-
ment. PRRSV inactivated with a dose of
1.5 kGy was still infectious, while PRRSV
inactivated with a dose of 2 kGy was no longer
infectious, but could not efﬁciently internalize
into macrophages. At this dose viral entry-asso-
ciated domains are most likely destroyed due to
the formation of free radicals which damage
proteins [24]. This viral protein degradation
was also seen on Western blot. In conclusion,
gamma irradiation is not suitable as a method
to inactivate PRRSV.
Temperature inactivation has been docu-
mented to inactivate viruses by denaturation
[31, 56]. As with protein cross-linking, denatur-
ation of viral proteins may also destroy the
entry-associated domains of PRRSV. However,
a modest increase of temperature (37 C) did
not prevent PRRSV to attach to and internalize
into macrophages, while preventing viral repli-
cation. Incubating PRRSV at 37 C would thus
be an interesting option to generate a killed
PRRSV vaccine. Clearly, inactivation at 37 C
does not result in denaturation of viral proteins.
This is conﬁrmed by Western blotting, since no
difference was observed in the banding pattern
between not inactivated control virus and inac-
tivated virus. However, since the mechanism of
inactivation is unknown, it might not be safe to
use this method to inactivate PRRSV for vac-
cine development.
Of all methods tested, the most promising
methods to inactivate PRRSV for KV vaccine
development are UV and BEI, because they
mainly have an effect on genomic level, pre-
serving entry-associated viral domains. This
was shown by internalization of the inactivated
virus into macrophages. However, for UV the
destruction of capsid proteins has been reported
[40]. Western blot analysis in this study indeed
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showed degradation of viral proteins upon UV
inactivation.
By investigating internalization into macro-
phages, the possibility exists that the inactivated
virus is taken up by phagocytosis instead of
using the PRRSV entry receptor Sn. However,
PRRSV inactivated by UV and BEI did also
attach to and internalized into macrophages
after treatment with a phagocytosis inhibitor.
These results conﬁrm that inactivated PRRSV
could still interact with PRRSV receptors and
that thus internalization of BEI or UV inacti-
vated PRRSV into macrophages did not occur
via phagocytosis.
In summary, the results of this study show
that inactivation methods that have a direct
effect on viral proteins, like formaldehyde, glu-
taraldehyde and changing the pH are not good
candidates for viral inactivation, as they do
not conserve viral entry-associated domains.
On the other hand, UV, BEI and gamma irradi-
ation, which mainly have an effect on the gen-
ome, could be interesting methods to inactivate
PRRSV for vaccine development, as inactivated
virus is still able to internalize into macro-
phages, but no longer replicates. However,
UV and gamma irradiation may give problems
with photoproducts or free radicals formed dur-
ing irradiation, which in turn could indirectly
degrade viral proteins. This study also revealed
that exposure of PRRSV to increased tempera-
ture was an efﬁcient method of viral inactiva-
tion, but the mechanism of action still requires
further investigation.
To investigate if the methods that seem the
most suitable according to the in vitro screening
assay described in this study are indeed good
for preserving the immunogenicity of PRRSV
inactivated vaccines, new experimental vac-
cines based on BEI and UV inactivation will
be tested in animals.
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